Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03952325
Title Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Metastatic TNBC and Tesetaxel Monotherapy in Patients With HER2 Negative MBC (CONTESSA TRIO)
Acronym CONTESSA TRIO
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Odonate Therapeutics, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.